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Background
According to various reports and clinical studies mental
disorders represent a frequent sequela of chronic diseases.
In end stage renal disease, in particular, mood disorders
and more specifically major depression is met with a fre-
quency of 20-30% and is the most widely acknowledged
abnormality [1]. As a consequence, overall quality of life
as well as treatment compliance is severely impaired [2].
Omega-3 (Ω3) polyunsaturated fatty acids (PUFAs) have
been shown to reduce the risk and to treat mental disor-
ders including depression [3]. However, evidence to date,
remains obscure and recommendations must be given
with caution [4]. The aim of the present study was to eval-
uate the significance of Ω3 administration in the treat-
ment of depressive maintenance hemodialysis (HD)
patients.
Materials and methods
Forty-five (n=45) patients, 32 male and 13 female, mean
age 59.7±16.2 years, on maintenance HD were recruited.
Using the Hamilton Depression (HAMD) Scale, partici-
pants mood was evaluated at baseline. According to
HAMD scoring, patients were subdivided into two groups.
Group A comprised 29 patients with score 0-7 (absence of
depression), whereas group B included 16 patients scor-
ing higher that 7 (clinically significant depression). Sub-
jects were further evaluated in terms of socioeconomic,
clinical, laboratory parameters and presence of sleep dis-
orders (as assessed by Athens Insomnia Scale, AIS).
Depressive patients (group B), received 1 gr of Ω3 PUFAs
(eicosapentaenoic acid and docosahexaenoic acid) daily
for a study period of 16 weeks, at the end of which mental
status, social and medical parameters were reassessed.
Results
Fourteen out of 16 participants completed 16 weeks of
treatment, one patient received a renal transplant and one
refused to comply. Non-significant changes of serum cre-
atinine, serum urea, electrolytes, albumin and haemo-
globin levels were observed during the intervention
period. Total serum cholesterol, serum triglycerides, LDL-
C and VLDL-C levels decreased at 16 week, although
changes were not statistically significant. Furthermore,
serum HDL-C levels significantly increased from
36.0±8.87 mg/dl at baseline to 39.6±8.93 mg/dl at week
16 (p=0.002). Most importantly, there was a significant
improvement in the mood of participants, as evidenced
by the reduction of mean HAMD scores from 16.64±6.39
to 13.79.69±6.07 (p=0.001). On the other hand, Ω3
PUFAs did not seem to influence sleep disturbances since
no alteration in patients AIS scores were observed
throughout the study period.
Conclusions
We conclude that administration of Ω3 PUFA could be
associated with a clinically significant mood improve-
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ment in patients with end stage renal disease and depres-
sion. Further research is required to elucidate the role of
polyunsaturated Ω3 fatty acids as sole or as an adjuvant
therapeutic modality in the treatment of depressive main-
tenance hemodialysis patients.
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